MDT Medtronic plc

NYSE medtronic.com


$ 99.27 $ -1.10 (-1.1 %)    

Thursday, 20-Nov-2025 12:56:49 EST
QQQ $ 591.29 $ -20.38 (-3.33 %)
DIA $ 458.57 $ -8.11 (-1.74 %)
SPY $ 656.63 $ -16.27 (-2.42 %)
TLT $ 89.27 $ 0.28 (0.31 %)
GLD $ 374.07 $ -1.11 (-0.3 %)
$ 100.34
$ 100.21
$ 99.22 x 12
$ 99.32 x 22
$ 99.25 - $ 101.18
$ 76.99 - $ 102.59
12,429,759
na
128.7B
$ 0.63
$ 27.62
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-26-2025 07-25-2025 10-Q
2 06-20-2025 04-25-2025 10-K
3 02-25-2025 01-24-2025 10-Q
4 11-26-2024 10-25-2024 10-Q
5 08-27-2024 07-26-2024 10-Q
6 06-20-2024 04-26-2024 10-K
7 02-27-2024 01-26-2024 10-Q
8 11-30-2023 10-27-2023 10-Q
9 08-31-2023 07-28-2023 10-Q
10 06-22-2023 04-28-2023 10-K
11 03-01-2023 01-27-2023 10-Q
12 12-01-2022 10-28-2022 10-Q
13 09-01-2022 07-29-2022 10-Q
14 06-23-2022 04-29-2022 10-K
15 03-03-2022 01-28-2022 10-Q
16 12-02-2021 10-29-2021 10-Q
17 09-02-2021 07-30-2021 10-Q
18 06-25-2021 04-30-2021 10-K
19 03-05-2021 01-29-2021 10-Q
20 12-03-2020 10-30-2020 10-Q
21 09-03-2020 07-31-2020 10-Q
22 06-19-2020 04-24-2020 10-K
23 02-28-2020 01-24-2020 10-Q
24 12-03-2019 10-25-2019 10-Q
25 08-30-2019 07-26-2019 10-Q
26 06-21-2019 04-26-2019 10-K
27 03-01-2019 01-25-2019 10-Q
28 11-29-2018 10-26-2018 10-Q
29 08-31-2018 07-27-2018 10-Q
30 06-22-2018 04-27-2018 10-K
31 03-02-2018 01-26-2018 10-Q
32 12-04-2017 10-27-2017 10-Q
33 09-01-2017 07-28-2017 10-Q
34 06-27-2017 04-28-2017 10-K
35 03-03-2017 01-27-2017 10-Q
36 12-05-2016 10-28-2016 10-Q
37 09-07-2016 07-29-2016 10-Q
38 06-28-2016 04-29-2016 10-K
39 03-09-2016 01-29-2016 10-Q
40 12-09-2015 10-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 truist-securities-maintains-hold-on-medtronic-raises-price-target-to-110

Truist Securities analyst Richard Newitter maintains Medtronic (NYSE:MDT) with a Hold and raises the price target from $103 ...

 morgan-stanley-maintains-overweight-on-medtronic-raises-price-target-to-117

Morgan Stanley analyst Cecilia Furlong maintains Medtronic (NYSE:MDT) with a Overweight and raises the price target from $10...

 rbc-capital-maintains-outperform-on-medtronic-raises-price-target-to-118

RBC Capital analyst Shagun Singh maintains Medtronic (NYSE:MDT) with a Outperform and raises the price target from $111 to $...

 medtronics-q2-beat-rekindles-growth-story--but-analysts-say-its-not-enough-yet

Medtronic PLC's stock rose on strong Q2 results, driven by high demand in cardiovascular and diabetes businesses. Analysts ...

 ubs-maintains-neutral-on-medtronic-raises-price-target-to-102

UBS analyst Danielle Antalffy maintains Medtronic (NYSE:MDT) with a Neutral and raises the price target from $95 to $102.

 wells-fargo-maintains-overweight-on-medtronic-raises-price-target-to-114

Wells Fargo analyst Larry Biegelsen maintains Medtronic (NYSE:MDT) with a Overweight and raises the price target from $100 t...

 baird-maintains-neutral-on-medtronic-raises-price-target-to-109

Baird analyst David Rescott maintains Medtronic (NYSE:MDT) with a Neutral and raises the price target from $103 to $109.

 goldman-sachs-upgrades-medtronic-to-neutral-raises-price-target-to-111

Goldman Sachs analyst David Roman upgrades Medtronic (NYSE:MDT) from Sell to Neutral and raises the price target from $81 to...

 nasdaq-tumbles-over-1-ahead-of-nvidia-earnings-fear--greed-index-in-extreme-fear-zone

The CNN Money Fear and Greed index rose in fear level, remaining in Extreme Fear zone. U.S. stocks fell ahead of highly anticip...

 tech-stocks-drop-pharma-gains-as-sector-rotation-picks-up-whats-moving-markets-tuesday

Wall Street endured another wave of selling in tech stocks on Tuesday, with the Nasdaq 100 down more than 1% by midday in New Y...

 medtronic-exec-says-bigger-portion-of-tariff-hit-in-q3-then-will-have-carryover-into-fiscal-2027

- Reuters Citing Conf Call

 this-medical-device-maker-is-seeing-high-demand-in-cardiovascular-diabetes-business

Medtronic reports strong Q2 2026 results with sales of around $9 billion, surpassing estimates. Organic growth at 5.5%.

 medtronic-ceo-says-co-now-sees-fx-tailwind-for-fiscal-2026-revenue-of-625m-725m

- Reuters Citing Conf Call

 medtronic-raises-fy2026-adj-eps-guidance-from-560-566-to-562-566-vs-563-est

GuidanceThe company today raised its FY26 revenue growth and EPS guidance.The company raised its FY26 organic revenue growth gu...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION